Do compromises in clinical trials cause Venture Capital losses?

Do compromises in clinical trials cause Venture Capital losses?

Do compromises in clinical trials cause Venture Capital losses? In 2020 and 2021 Sunstone looked in depth at drug development venture-backed successes to find usable attributes and learn from the past. We have now turned the analysis up-side down and looked at the...

Who is in the driver’s seat of our industry?

A recent analysis from Pharma Intelligence | Informa 2021 highlights the current trends of pipeline products (top panel). We have subsequently surveyed Sunstone’s incoming deal flow for the same period and noted the correlation for the top 3 categories with oncology...

US IPO: Value recognition? Not really! Trading liquidity? Yes!

We previously looked at M&A of VC funded private and listed companies in the EU and US (https://bit.ly/3EU4n8H). Listing EU companies in the US is perceived as more attractive or beneficial – but is it reflected in the numbers?  Recently, we decided to take a...

Why would you do a US IPO?

We recently compared EUR >50M M&A’s of VC funded EU and US drug developing companies and concluded that a substantial difference exists between the EU and US (https://bit.ly/3uftQmU). Previously we have also looked at EU M&A’s before or after an IPO....

M&A multiples in the US – should you go west?

Sunstone has previously investigated the return multiples of venture capital funded companies HQ’ed in Europe (https://bit.ly/3n0bd3B) and concluded that when the total invested amount exceeds EUR 50M, the return multiple tends to stay below 5 in M&A transactions....
Best country for sourcing new deals?

Best country for sourcing new deals?

Do you also in your mind have a priority list of destinations to visit once the world normalises and you can get back on a plane? If so, and if you are a Venture Capitalist, you may also be wondering which countries have been creating most Life Science M&A...